Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Lomustine + Nab-rapamycin |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Lomustine | Belustine | CCNU | ||
| Nab-rapamycin | Fyarro | ABI-009|nab-sirolimus | mTORC1 Inhibitor 9 | Fyarro (nab-rapamycin) is nanoparticle albumin-bound rapamycin and inhibitor of mTOR that has immunosuppressant and anti-tumor activities (PMID: 24089446). Fyarro (nab-rapamycin) is FDA approved for use in patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03463265 | Phase II | Lomustine + Nab-rapamycin Nab-rapamycin Nab-rapamycin + Temozolomide Bevacizumab + Nab-rapamycin | ABI-009 (Nab-Rapamycin) in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma | Completed | USA | 0 |